Clinical Trials Logo

Leukemia, Other clinical trials

View clinical trials related to Leukemia, Other.

Filter by:
  • None
  • Page 1

NCT ID: NCT03555851 Recruiting - Leukemia, Other Clinical Trials

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Start date: July 13, 2018
Phase:
Study type: Observational

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).

NCT ID: NCT02560883 Recruiting - Leukemia, Other Clinical Trials

Hairy Cell Leukemia Patient Data Registry

HCL-PDR
Start date: January 2, 2013
Phase:
Study type: Observational

The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in partnership with investigators from its Centers of Excellence, seeks to develop a registry to help researchers identify new trends in outcomes, recognize the most effective treatments, discover previously unknown complications of the disease, and design clinical trials for new therapies.

NCT ID: NCT00250042 Completed - Cancer Clinical Trials

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Start date: April 2004
Phase: Phase 2
Study type: Interventional

1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.